(VIANEWS) – NVIDIA (NVDA), Omega Healthcare Investors (OHI), BioMarin Pharmaceutical (BMRN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NVIDIA (NVDA)
224.6% sales growth and 69.17% return on equity
NVIDIA Corporation provides graphics, and compute and networking solutions in the United States, Taiwan, China, and internationally. The company's Graphics segment offers GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, and solutions for gaming platforms; Quadro/NVIDIA RTX GPUs for enterprise workstation graphics; vGPU software for cloud-based visual and virtual computing; automotive platforms for infotainment systems; and Omniverse software for building 3D designs and virtual worlds. Its Compute & Networking segment provides Data Center platforms and systems for AI, HPC, and accelerated computing; Mellanox networking and interconnect solutions; automotive AI Cockpit, autonomous driving development agreements, and autonomous vehicle solutions; cryptocurrency mining processors; Jetson for robotics and other embedded platforms; and NVIDIA AI Enterprise and other software. The company's products are used in gaming, professional visualization, datacenter, and automotive markets. NVIDIA Corporation sells its products to original equipment manufacturers, original device manufacturers, system builders, add-in board manufacturers, retailers/distributors, independent software vendors, Internet and cloud service providers, automotive manufacturers and tier-1 automotive suppliers, mapping companies, start-ups, and other ecosystem participants. It has a strategic collaboration with Kroger Co. NVIDIA Corporation was incorporated in 1993 and is headquartered in Santa Clara, California.
Earnings Per Share
As for profitability, NVIDIA has a trailing twelve months EPS of $7.6.
PE Ratio
NVIDIA has a trailing twelve months price to earnings ratio of 74.17. Meaning, the purchaser of the share is investing $74.17 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 69.17%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 411.4% and 380.6%, respectively.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Dec 4, 2023, the estimated forward annual dividend rate is 0.16 and the estimated forward annual dividend yield is 0.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 205.5%, now sitting on 44.87B for the twelve trailing months.
Previous days news about NVIDIA(NVDA)
- The zacks analyst blog highlights NVIDIA, Boeing, Sony group, charles schwab and synopsys. According to Zacks on Monday, 15 January, "Stocks recently featured in the blog include: NVIDIA Corp. (NVDA Quick QuoteNVDA – Free Report) , The Boeing Co. (BA Quick QuoteBA – Free Report) , Sony Group Corp. (SONY Quick QuoteSONY – Free Report) , The Charles Schwab Corp. (SCHW Quick QuoteSCHW – Free Report) and Synopsys, Inc. (SNPS Quick QuoteSNPS – Free Report) .", "However, its near-term prospects are likely to be hurt by softening IT spending amid macroeconomic headwinds.(You can read the full research report on NVIDIA here >>>)Shares of Boeing have outperformed the Zacks Aerospace – Defense industry over the past year (+4% vs. -6.8%). "
- According to Zacks on Monday, 15 January, "Some other top-ranked stocks from the broader technology sector are Zoom Video Communications Inc. (ZM Quick QuoteZM – Free Report) , NVIDIA Corporation (NVDA Quick QuoteNVDA – Free Report) and Amazon.com (AMZN Quick QuoteAMZN – Free Report) . ", "While Zoom sports a Zacks Rank #1, NVIDIA and Amazon each carry a Zacks Rank #2 (Buy). "
2. Omega Healthcare Investors (OHI)
12.5% sales growth and 6.17% return on equity
Omega is a REIT that invests in the long-term healthcare industry, primarily in skilled nursing and assisted living facilities. Its portfolio of assets is operated by a diverse group of healthcare companies, predominantly in a triple-net lease structure. The assets span all regions within the U.S., as well as in the U.K.
Earnings Per Share
As for profitability, Omega Healthcare Investors has a trailing twelve months EPS of $0.98.
PE Ratio
Omega Healthcare Investors has a trailing twelve months price to earnings ratio of 31.34. Meaning, the purchaser of the share is investing $31.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.17%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Omega Healthcare Investors’s EBITDA is 55.19.
Yearly Top and Bottom Value
Omega Healthcare Investors’s stock is valued at $30.71 at 00:22 EST, way under its 52-week high of $34.77 and way higher than its 52-week low of $25.61.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Oct 29, 2023, the estimated forward annual dividend rate is 2.68 and the estimated forward annual dividend yield is 8.82%.
3. BioMarin Pharmaceutical (BMRN)
10% sales growth and 3.11% return on equity
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops valoctocogene roxaparvovec, an adeno associated virus vector, which is in Phase III clinical trial for the treatment of patients with severe hemophilia A; BMN 307, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial to normalize blood Phe concentration levels in patients with PKU; and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
Earnings Per Share
As for profitability, BioMarin Pharmaceutical has a trailing twelve months EPS of $0.77.
PE Ratio
BioMarin Pharmaceutical has a trailing twelve months price to earnings ratio of 124.53. Meaning, the purchaser of the share is investing $124.53 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.11%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
BioMarin Pharmaceutical’s EBITDA is 232.97.
4. ITT Corporation (ITT)
9.8% sales growth and 19.51% return on equity
ITT Inc. manufactures and sells engineered critical components and customized technology solutions for the energy, transportation, and industrial markets worldwide. The company operates through three segments: Motion Technologies, Industrial Process, and Connect & Control Technologies. The Motion Technologies segment manufactures brake pads, shims, shock absorbers, and energy absorption components; and sealing technologies primarily for the transportation industry, including passenger cars, light- and heavy-duty commercial and military vehicles, buses, and rail. The Industrial Process segment designs and manufactures industrial pumps, valves, and plant optimization systems; and centrifugal process pumps, twin screw, axials, and positive displacement pumps, and water systems, as well as aftermarket solutions, such as repairs and upgrades services. It serves various customers in industries, such as chemical, oil and gas, mining, and other industrial process markets. The Connect & Control Technologies segment designs and manufactures a range of engineered connectors and specialized control components for critical applications supporting various markets, including aerospace and defense, industrial, transportation, medical, and oil and gas. The connector product portfolio includes electrical connectors, such as circular, rectangular, radio frequency, fiber optic, D-sub miniature, micro-miniature, and cable assemblies; and control products consist of fuel and water pumps, valves, electro-mechanical rotary and linear actuators, and pressure, temperature, limit, and flow switches for various aircraft systems. ITT Inc. was founded in 1920 and is headquartered in White Plains, New York.
Earnings Per Share
As for profitability, ITT Corporation has a trailing twelve months EPS of $5.24.
PE Ratio
ITT Corporation has a trailing twelve months price to earnings ratio of 22.08. Meaning, the purchaser of the share is investing $22.08 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.51%.
Sales Growth
ITT Corporation’s sales growth is 5.2% for the current quarter and 9.8% for the next.
Yearly Top and Bottom Value
ITT Corporation’s stock is valued at $115.72 at 00:22 EST, below its 52-week high of $121.19 and way higher than its 52-week low of $75.82.
5. Grand Canyon Education (LOPE)
6.9% sales growth and 31.45% return on equity
Grand Canyon Education, Inc. provides education services to colleges and universities in the United States. The company's technology services include learning management system, internal administration, infrastructure, and support services; academic services comprises program and curriculum, faculty and related training and development, class scheduling, and skills and simulation lab sites; and counseling services and support include admission, financial aid, and field experience counseling services. It also offers marketing and communication services, such as lead acquisition, digital communications strategy, brand identity, media planning and strategy, video, and data science and analysis services; and back office services comprising finance and accounting, human resources, audit, procurement services. The company, through its subsidiary, Orbis Education Services, LLC, supports healthcare education programs for 22 universities. Grand Canyon Education, Inc. was founded in 1949 and is based in Phoenix, Arizona.
Earnings Per Share
As for profitability, Grand Canyon Education has a trailing twelve months EPS of $6.36.
PE Ratio
Grand Canyon Education has a trailing twelve months price to earnings ratio of 19.73. Meaning, the purchaser of the share is investing $19.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.45%.
Moving Average
Grand Canyon Education’s value is under its 50-day moving average of $135.27 and higher than its 200-day moving average of $117.36.
Sales Growth
Grand Canyon Education’s sales growth is 6.3% for the current quarter and 6.9% for the next.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 15.3% and 11%, respectively.
